There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
The need to enhance the immunogenicity of purified subunit antigens has prompted the
development of new adjuvants. The adjuvant emulsion MF59 has been tested in animals
in combination with different antigens and finally evaluated in humans. It was licensed
after the successful outcome of preclinical and clinical testing. This paper summarizes
the main characteristics of the MF59 adjuvant, including animal testing, clinical
experience with various vaccines, and information from current postmarketing surveillance
data. This review supports the hypothesis that MF59 is a safe adjuvant for human use.